Irritable Bowel Syndrome News and Research RSS Feed - Irritable Bowel Syndrome News and Research

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine, often causing bouts of cramping, abdominal pain, bloating, diarrhea and constipation.

IBS is not curable but, in most cases, people learn to live with and control the condition by managing diet, lifestyle and stress levels. Medications to treat diarrhea, pain killers or drugs that relieve painful bowel spasms may also be used.

The cause of IBS is not yet clear but it is linked to changes in the way food is moved through the bowel. In healthy people, layers of muscle lining the intestinal wall contract and relax in a coordinated manner to move food from the stomach, through the colon and into the rectum. When an individual has IBS, however, the contractions are unusually strong and food is passed through the intestine too quickly which leads to diarrhea and a build up of gas.

Triggers for IBS range from pressure on the intestines to certain foods such as chocolate or carbonated drinks, hormonal changes such as during the menstrual cycle and emotional changes such as an increase in stress.

IBS can be painful and debilitating if not treated appropriately, negatively impacting on a person’s quality of life. However, with appropriate treatment individuals with IBS should be able to live a full and active life.
Children who eat certain types of food more likely to contract Epstein-Barr virus

Children who eat certain types of food more likely to contract Epstein-Barr virus

A new study by UNC Charlotte scholars is shedding light on the connection between diet and a common childhood disease. [More]
Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics begins SYN-004 Phase 2a clinical trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). [More]
The Medical Minute highlights risk and symptoms of IBD in children

The Medical Minute highlights risk and symptoms of IBD in children

Occasional stomach aches are part of life. But when they continue for more than a few weeks, come back often or are accompanied by bloody stools and additional symptoms, the cause could be inflammatory bowel disease, or IBD. [More]
AGA receives gift to support young investigators advance into neuroenteric disease research

AGA receives gift to support young investigators advance into neuroenteric disease research

The American Gastroenterological Association Research Foundation has received a generous gift from prominent San Francisco philanthropist Athena Blackburn, which will create new research opportunities for young investigators who are interested in neuroenteric disease. [More]
Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis provides overview of standalone global pharmaceutical development pipeline

Actavis plc, during its Investor Meeting in New York, today provided a detailed look into its standalone global pharmaceutical development pipeline that supports the Company's long-term organic growth. The Company provided details regarding key development programs, including clinical data, development milestones and an overview of potential market opportunities, as well as an updated look at Actavis' world-class generics pipeline, which continues to hold an industry-leading position in First-to-File opportunities in the U.S. [More]
Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics reports positive results from SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced positive topline safety and tolerability results from a Phase 1b clinical trial of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
News study finds association between chronic fatigue syndrome and early menopause

News study finds association between chronic fatigue syndrome and early menopause

A newfound link between chronic fatigue syndrome (CFS) and early menopause was reported online today in Menopause, the journal of The North American Menopause Society. [More]
Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics doses first patient in SYN-004 Phase 1b trial to prevent C. difficile infection

Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy. [More]
Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen's Somatuline Depot Injection 120 mg receives FDA approval for treatment of GEP-NETs

Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, today announced that Somatuline Depot (lanreotide) Injection 120 mg (referred to as Somatuline) was approved by the U.S. Food and Drug Administration for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS). [More]
New oral medication shows promise in treating fibromyalgia

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial. [More]
Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014. [More]
Denmark researchers calculate the real burden of foodborne infections

Denmark researchers calculate the real burden of foodborne infections

Campylobacter is the foodborne bacteria that contributes most to the burden of disease in Denmark. This is the finding of a study from the National Food Institute, Technical University of Denmark, which for the first time in Denmark ranks three foodborne bacteria according to the burden of disease they impose on society as a whole. [More]
New AGA guidelines provide guidance on IBS treatments

New AGA guidelines provide guidance on IBS treatments

Up to 15 percent of the general adult population is affected by irritable bowel syndrome (IBS), and most patients struggle to find effective drug therapy. A new guideline from the American Gastroenterological Association provides these patients and their physician's guidance. [More]
Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

GEP-NETs stands for gastroenteropancreatic (GEP) neuroendocrine tumors (NETs). This is a type of rare cancer that is increasing in incidence and prevalence – more on this later. [More]
UB study: Males with IBS experience more interpersonal difficulties than females

UB study: Males with IBS experience more interpersonal difficulties than females

One of the few studies to examine gender differences among patients with irritable bowel syndrome (IBS) has found that males with the condition experience more interpersonal difficulties than do females with the condition. [More]
Obeticholic acid drug shows promise against bile acid diarrhoea

Obeticholic acid drug shows promise against bile acid diarrhoea

A pilot study testing a new type of drug in patients with chronic diarrhoea has shown promising effects on reducing their symptoms. [More]
Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. [More]
Depression contributes to abnormal pain processes in IBS patients

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms. [More]
Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx announces positive Phase 2b results for tenapanor in IBS-C patients

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). [More]
Intimate partner violence may trigger irritable bowel syndrome, insomnia

Intimate partner violence may trigger irritable bowel syndrome, insomnia

One in five men in the U.S. reports violence towards their spouse or significant other, says a new nationally-representative study by the University of Michigan. [More]
Advertisement